FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

On November 21, 2016, the U.S. Food and Drug Administration granted regular approval to daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was base...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Bhatnagar, Vishal, Gormley, Nicole J., Luo, Lola, Shen, Yuan Li, Sridhara, Rajeshwari, Subramaniam, Sriram, Shen, Guoxiang, Ma, Lian, Shord, Stacy, Goldberg, Kirsten B., Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2017
Schlagworte:
Regulatory Issues: FDA
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679834/
https://ncbi.nlm.nih.gov/pubmed/28904172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0229
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge